Although G179X are considered sensitizing mutations, these were not included in a phase 3 trial comparing osimertinib with other EGFR-TKIs for EGFR-mutant NSCLC patients as first line (FLAURA)3 and are under-represented in clinical trials compared to exon 19del and L858R. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.